Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2002

01-10-2002 | Adis New Drug Profile

Biapenem

Authors: Caroline M. Perry, Tim Ibbotson

Published in: Drugs | Issue 15/2002

Login to get access

Abstract

  • ▴ Biapenem is a new parenteral carbapenem antibacterial agent with a broad spectrum of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases.
  • ▴ Biapenem is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor.
  • ▴ After intravenous administration, biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid).
  • ▴ In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.
  • ▴ Biapenem is generally well tolerated. The most common adverse events in clinical trials were skin eruptions/rashes, nausea and diarrhoea.
Literature
1.
Yang Y, Testa RT, Bhachech N, et al. Biochemical characterization of novel tetrahydrofuranyl 1β- methylcarba-penems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother 1999 Dec; 43(12): 2904–9PubMed
2.
Felici A, Perilli M, Segatore B, et al. Interactions of biapenem with active-site serine and metallo-β- lactamases. Antimicrob Agents Chemother 1995 Jun; 39(6): 1300–5PubMedCrossRef
3.
Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995 Jan; 35(1): 75–84PubMedCrossRef
4.
Ubukata K, Sugiura M, Konno M. In vitro activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 20–5
5.
Kashitani F, Fukuzawa S, Mori C, et al. In vitro activities of carbapenem antibiotics against the various clinical isolates [abstract] [in Japanese]. Jpn J Antibot 2000 Jan; 53(1): 25
6.
Ubukata K, Chiba N, Kobayashi R, et al. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother Jpn 2002 Jan; 50(1): 1–10
7.
Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30: 129–34PubMedCrossRef
8.
Hikida M, Kawashima K, Nishiki K, et al. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992 Feb; 36(2): 481–3PubMedCrossRef
9.
Sader HS, Gales AC. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents. Drugs 2001; 61(5): 553–64PubMedCrossRef
10.
Day IP, Goudie J, Nishiki K, et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995 Apr; 76(3): 239–43PubMedCrossRef
11.
Hikida M, Masukawa Y, Nishiki K, et al. Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993 Feb; 37(2): 199–202PubMedCrossRef
12.
Hori S, Kanemitsu K, Shimada J. Relation between convulsant activity of biapenem, a new carbapenem, and its binding affinity to GABA receptor [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 115–20
13.
Hoban DJ, Jones RN, Yamane N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1993 Nov 1993 31; 17(4): 299–305
14.
Igari J, Inoue M, Nishino T, et al. Survey of sensitivities of clinical isolates to antibacterial agents (annual report) [in Japanese]. Jpn J Antibiot 1997 Aug; 50(8): 683–703PubMed
15.
Igari J, Watanabe N, Uehara N, et al. Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents [in Japanese]. Jpn J Antibiot 2000 Mar; 53(3): 157–70
16.
Watanabe A, Kikuchi H, Kikuchi T, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother 1999 Sep; 5(3): 171–5PubMedCrossRef
17.
Suzuki Y, Nishinari C, Endo H, et al. Antimicrobial activities of carbapenems and forth generation cephems against clinically isolated strains [in Japanese]. Jpn J Antibiot 2001 Sep; 54(9): 473–90PubMed
18.
Catchpole CR, Wise R, Thornber D, et al. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992 Sep; 36(9): 1928–34PubMedCrossRef
19.
Bonfiglio G, Maccarone G, Mezzatesta ML, et al. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates. Chemotherapy 1997 Nov 31; 43(6): 393PubMedCrossRef
20.
Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother 1990 Jun; 34(6): 994–1000PubMedCrossRef
21.
Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of gram- positive and gram-negative bacteria. Antimicrob Agents Chemother 1993 Sep; 37(9): 2009–16PubMedCrossRef
22.
Neu HC, Gu JW, Fang W, et al. In vitro activity and beta-lactamase stability of LJC 10,627. Antimicrob Agents Chemother 1992 Jul; 36(7): 1418–23PubMedCrossRef
23.
Watanabe A, Tokue Y, Takahashi H, et al. In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996–1998 [in Japanese]. Jpn J Antibiot 1999 Dec; 52(12): 690–4PubMed
24.
Yoshida M, Watanabe M, Mitsuhashi S. In vitro antibacterial activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 1–19
25.
Raymond NJ, Bremner DA. The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother 1995 May; 35(5): 681–6PubMedCrossRef
26.
Murase M. In vitro antibacterial activities of carbapenems against clinical isolates [in Japanese]. Jpn J Antibiot 1999 Nov; 52(11): 667–79PubMed
27.
Alonso R, Fernandez-Aranguiz A, Colom K, et al. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 1994 Oct; 13(10): 820–2PubMedCrossRef
28.
Chen HY, Livermore DM. Comparative in-vitro activity of biapenem against enterobacteria with β-lactamase-mediated antibiotic resistance. J Antimicrob Chemother 1994 Mar; 33(3): 453–64PubMedCrossRef
29.
Watanabe A, Tokue Y, Takahashi H, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001 Dec; 7(4): 267–71PubMedCrossRef
30.
Fujiue Y, Kuwabara M, Muroki K, et al. The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum [in Japanese]. Jpn J Antibiot 1998 Jan; 51(1): 26–36PubMedCrossRef
31.
Hirakata Y, Matsuda J, Mochida C, et al. Annual changes is susceptibility of clinical isolates to biapenem [in Japanese]. Jpn J Chemother 2002; 50(6): 329–51
32.
Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994 May; 33(5): 949–58PubMedCrossRef
33.
Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiot (Tokyo) 1997 Feb; 50(2): 135–8CrossRef
34.
Hikida M, Terashima S, Sato Y, et al. Comparative antibacterial activity of carbapenems againstP. aeruginosa (1) [in Japanese]. Jpn J Antibiot 2001 Nov; 54(11): 571–9PubMed
35.
Hikida M, Mori M, Kitta T. In vitro evaluation of biapenem, a new carbapenem antibiotic. Chemotherapy 1994 Dec; 42(S-4): 101
36.
Simor AE, Louie L, Louie M. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/ tazobactam and thirteen other antimicrobial agents [letter]. Eur J Clin Microbiol Infect Dis 1994 Jun; 13(6): 521–3PubMedCrossRef
37.
Clarke AM, Zemcov SJV. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993; 12(5): 377–84PubMedCrossRef
38.
Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994 Apr; 38(4): 898–900PubMedCrossRef
39.
Weiss WJ, Petersen PJ, Jacobus NV, et al. In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems. Antimicrob Agents Chemother 1999 Mar; 43(3): 454–9PubMed
40.
Chiba N, Kobayashi R, Hasegawa K. Activity of biapenem and 7 other antimicrobial agents against Streptococcus pneumoniae [in Japanese]. Jpn J Chemother 2002 Mar; 50(3): 161–70
41.
Saito A, Inamatsu T, Okada T, et al. Committee Report: Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released [in Japanese]. J Infect Chemother 1999; 5(4): 223–6PubMedCrossRef
42.
Aldridge KE, Morice N, Schiro DD. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994 Apr; 38(4): 889–93PubMedCrossRef
43.
Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano-Martin I, et al. L-627, a novel carbapenem: in-vitro activity against anaerobes [letter]. J Antimicrob Chemother 1994 Jan; 33(1): 183–6PubMedCrossRef
44.
Wexler HM, Molitoris E, Finegold SM. The in-vitro activity of L-627 against anaerobic bacteria. J Antimicrob Chemother 1994 Mar; 33(3): 629–34PubMedCrossRef
45.
Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993 Aug; 32(2): 223–31PubMedCrossRef
46.
Nord CE, Lindmark A, Persson I. In vitro activity of L-627 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992 Aug; 11(8):757–60PubMedCrossRef
47.
Miyake Y, Fujiwara S, Usui T, et al. In vitro antibacterial activity of biapenem against adherent bacteria [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 82–90
48.
Hiraishi T, Miyata A, Hara T, et al. Bactericidal activity of biapenem against various bacteria [in Japanese]. Jpn J Antibiot 2001 Dec; 54(12): 581–95PubMed
49.
Hiraishi T, Miyata A, Takata T. Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa [in Japanese]. Jpn J Antibot 2002 Feb; 55(1): 76
50.
Hikida M, Yamazaki Y, Yoshida M, et al. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. J Antibiot (Tokyo) 1995 Aug; 48(8): 891–2CrossRef
51.
Houston AK, Jones RN. Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species. J Chemother 1994 Feb; 6(1): 12–4PubMed
52.
Nakashima M, Uematsu T, Ueno K, et al. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Clin Pharmacol Ther Toxicol 1993 Feb; 31(2): 70–6PubMed
53.
Tarao F, Miura T, Saito A, et al. Pharmacokinetic study of biapenem [in Japanese]. Jpn J Chemother 1996; 44(10): 769–75
54.
Nagashima S, Kozawa O, Otsuka T, et al. Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis. J Anti-microb Chemother 2000 Nov; 46(5): 839–42
55.
Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998 Jun; 42(6): 1433–6PubMed
56.
Meiji. Omegacin® (biapenem) prescribing information [in Japanese]. Kanagawa, Japan: Meiji, 2002
57.
Koeppe P, Hoffler D, Fitzen B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung 1997 Nov; 47(11): 1250–6PubMed
58.
Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydro-peptidase-I. J Antimicrob Chemother 1996 May; 37: 1034–6PubMedCrossRef
59.
Brismar B, Akerlund JE, Sjostedt S, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Scand J Infect Dis 1996; 28(5): 507–12PubMedCrossRef
60.
Matsumoto F, Inoue M, Sakurai I, et al. Dose-comparison study on biapenem in the treatment of chronic bronchitis [in Japanese]. Jpn J Chemother 2000; 48(1): 34–44
61.
Matsumoto F, Inoue M, Sakurai I, et al. A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections [in Japanese]. Jpn J Chemother 2000; 48(1): 45–67
62.
Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for chronic respiratory tract infection [in Japanese]. Jpn J Chemother 1995; 43(1): 63–84
63.
Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for bacterial pneumonia [in Japanese]. Jpn J Chemother 1995; 43(1): 41–62
64.
Kawada Y, Deguchi T, Kumamoto Y, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infection [in Japanese]. Chemotherapy 1994; 42(12): 1368–84
65.
Kawada Y, Deguchi T, Tsukamoto T, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2000; 48(3): 218–32
66.
Kawada Y, Deguchi T, Kawabe K, et al. Dose-finding study of biapenem in complicated urinary tract infections [in Japanese]. Jpn J Chemother 1999; 47(12): 852–62
67.
Hara K, Baba S, Matsumoto F, et al. Clinical evaluation of biapenem in various infectious diseases [in Japanese]. Jpn J Antibiot 1999 Nov; 52(11): 629–60PubMed
68.
Baba S, Miyamoto N, Ichikawa G, et al. Laboratory and clinical findings on L-627 (biapenem) in otorhinolaryngological infections [in Japanese]. Jibi To Rinsho 1995; 41(No. 3): 495–509
Metadata
Title
Biapenem
Authors
Caroline M. Perry
Tim Ibbotson
Publication date
01-10-2002
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200262150-00005

Other articles of this Issue 15/2002

Drugs 15/2002 Go to the issue

Adis Drug Evaluation

Danaparoid

Adis New Drug Profile

Gefitinib

Adis New Drug Profile

Gefitinib

Adis Drug Evaluation

Budesonide (Entocort® EC Capsules)

Adis New Drug Profile

Biapenem

Adis New Drug Profile

Extended-Release Methylphenidate (Ritalin® LA)